相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DPYDandUGT1A1Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation
Lisa A. Varughese et al.
PHARMACOTHERAPY (2020)
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M. Henricks et al.
EUROPEAN JOURNAL OF CANCER (2019)
Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks
Marie-Anne Loriot et al.
BULLETIN DU CANCER (2018)
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M. Henricks et al.
LANCET ONCOLOGY (2018)
DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update
L. M. Henricks et al.
ANNALS OF ONCOLOGY (2017)
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
Didier Meulendijks et al.
BRITISH JOURNAL OF CANCER (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Maarten J. Deenen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer A Secondary Analysis of the PETACC-8 Randomized Clinical Trial
Valerie Boige et al.
JAMA ONCOLOGY (2016)
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines
Giuseppe Toffoli et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks et al.
LANCET ONCOLOGY (2015)
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)
Adam M. Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis
Salvatore Terrazzino et al.
PHARMACOGENOMICS (2013)
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group
Matthias Schwab et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel et al.
MOLECULAR CANCER THERAPEUTICS (2006)
How may anticancer chemotherapy with fluorouracil be individualised?
Su-arpa Ploylearmsaeng et al.
CLINICAL PHARMACOKINETICS (2006)
American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
AB Benson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
